Boston Area Diabetes Endocrinology Research Center

波士顿地区糖尿病内分泌学研究中心(BADERC)是一个由69名实验室和临床研究人员组成的联盟，他们致力于解决与1型和2型糖尿病的病因、发病机制、治疗和治愈及其相关的微血管和动脉粥样硬化并发症有关的许多主要研究问题。中心主任(Joseph Avruch)和副主任(Joel F.Habener和Brian Seed)是在信号转导、基因表达、分子生物学和免疫学方面具有国际地位的高生产率高级研究人员，这些主题是糖尿病研究进展的核心。参与研究的科学家在波士顿地区的大量研究机构工作，其中大多数在哈佛医学院附属的主要机构工作 教学医院(马萨诸塞州总医院、布里格姆妇女医院、贝丝以色列女执事医疗中心)和波士顿大学医学中心，以及哈佛大学文理学院、其他哈佛附属研究机构(公共卫生学院、达纳-法伯癌症中心、谢彭斯眼科研究所)、新英格兰医学中心和麻省理工学院的几个研究机构 技术。这些研究人员致力于与确定1型和2型糖尿病的发病机制和最佳治疗方法最相关的前沿领域：胰岛素作用和胰岛素抵抗的分子和遗传学基础；血管系统和β细胞的生物学；自身免疫和移植排斥反应的免疫学基础和最佳治疗方法；甘油监测和控制的新方法的开发。BADERC为这些科学家提供一系列核心支持服务(分子生物学；细胞生物学和形态学； 转基因；放射免疫分析和克隆抗体生成；荧光激活细胞分选；代谢生理学)，结合了公认专家在分子遗传学、细胞生物学和代谢生理学方面的最新技术进步。大多数核心课程在很大程度上侧重于实践培训。在上一个授标期内，对这些服务进行了相当大的扩展和升级，而且这些服务的利用具有成本效益， 高质量的支持服务一直很强劲。一个新的蛋白质组学核心被提出，准备为实验室和临床研究人员提供服务。BADERC赞助了一项竞争激烈的试点和可行性赠款计划。18位获奖者卓有成效，并以良好的比率获得了独立的支持。具有成本效益的卓越质量的支持服务以及教育和试点资助计划促进了新的计划和合作，并吸引了来自这一杰出科学界的新人才进入糖尿病研究。该中心还寻求促进实验室和临床科学家之间的最密切互动，以确保将研究发现转化为糖尿病患者护理方面的进步。

The Boston Area Diabetes Endocrinology Research Center (BADERC) is a consortium of 69 laboratory-based and clinical investigators whose efforts are directed toward addressing many of the major research questions bearing on the etiology, pathogenesis, treatment and cure of type 1 and type 2 diabetes, and their associated microvascular and atherosclerotic complications. The center director {Joseph Avruch) and associates directors (Joel F. Habener and Brian Seed) are highly productive senior investigators of international stature in signal transduction, gene expression, molecular biology and immunology, topics central to advances in diabetes research. The participating scientists are based at a large number of Boston-area research institutions, with the majority at the major Harvard Medical School-affiliated teaching hospitals (the Massachusetts General Hospital, the Brigham and Women's Hospital, the Beth Israel-Deaconess Medical Center) and the Boston University Medical Center, as well as several at the Harvard School of Arts and Sciences, other Harvard-affiliated research institutions (School of Public Health, the Dana-Farber Cancer Center, the Schepens Eye Research Institute), the New England Medical Center and the Massachusetts Institute of Technology. These investigators are working at the cutting edge of fields most relevant to defining the pathogenesis and optimal treatment of type 1 and type 2 diabetes: The molecular and genetic basis of insulin action and insulin resistance; the biology of the vascular system and beta cell; the immunologic basis and optimal therapies for autoimmunity and transplant rejection; the development of new methods for glycernic monitoring and control. The BADERC offers these scientists an array of core support services (Molecular Biology; Cell Biology & Morphology; Transgenics; Radioimmunoassay and Monoclonal Antibody Generation; Fluorescent activated cell sorting; Metabolic Physiology) that incorporate the latest technical advances in molecular genetics, cell biology, and metabolic physiology provided by acknowledged experts. Most cores are heavily oriented towards hands-on training. Considerable expansion and upgrading of these services has occurred over the prior award period, and the utilization of these cost-effective, high quality support services has been robust. A new Proteomics core is proposed, poised to service both laboratory-based and clinical investigators. The BADERC sponsors a highly competitive program of pilot and feasibility grants. The 18 awardees have been productive and have progressed toward independent support at a good rate. The availability of cost effective support services of outstanding quality together with the educational and pilot grants program has catalyzed new programs and collaborations, and attracted to diabetes research new talent from this outstanding scientific community. The center seeks also to foster the closest interactions between the laboratory based and clinical scientists, so as to ensure the translation of research discoveries into advances in the care of diabetic patients.